Related Experiment Video
Updated: May 1, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Should academic therapeutic patents go to the highest bidder?
Bryan Collinsworth1, Sara E Crager
1Universities Allied for Essential Medicines (UAEM), Sarah Lawrence College , 434 E 10th St #4, NY 10009 , USA +1 646 450 0752 ; +1 866 690 1178 ; bcollinsworth@uaem.org.
Abstract:
Universities conduct biomedical research with the self-stated goal of disseminating the benefits to the global public. Licensing therapeutic patents to the highest bidder is counterproductive to this aim, as it prioritizes income maximization over dissemination. We believe that licensing strategies focused on promoting broad access to university-discovered therapeutics better serve both the mission of universities and the public good.
Related Concept Videos
Clinical Trials: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Nomenclature
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioequivalence studies: Biowaivers
Preclinical Development: Overview

